- Home
- NCL vs MBRX Comparison
NCL vs MBRX Comparison
Compare NCL & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NCL | MBRX |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7M | 8.6M |
| IPO Year | 2023 | 2016 |
Fundamental Metrics
Financial Performance| Metric | NCL | MBRX |
|---|---|---|
| Price | $0.34 | $3.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $105.50 |
| AVG Volume (30 Days) | ★ 18.1M | 621.4K |
| Earning Date | 11-14-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $12,997,205.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.10 | $3.63 |
| 52 Week High | $12.16 | $91.25 |
Technical Indicators
Market Signals| Indicator | NCL | MBRX |
|---|---|---|
| Relative Strength Index (RSI) | 49.01 | 51.07 |
| Support Level | $0.10 | $3.74 |
| Resistance Level | $0.49 | $4.24 |
| Average True Range (ATR) | 0.07 | 0.57 |
| MACD | 0.00 | -0.33 |
| Stochastic Oscillator | 60.90 | 5.29 |
Price Performance
Historical ComparisonAbout NCL Northann Corp.
Northann Corp specialized in 3D-printed flooring solutions under its flagship brand, "Benchwick." The company's operations span the full spectrum of additive manufacturing, from sourcing recycled ocean plastics to the final production of intricate flooring designs. It offers an extensive range of proprietary solutions, including Infinite Glass, DSE, TruBevel, and MattMaster, mainly through its sales network in North America and Europe.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.